Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), bought 3,433 shares at $13.18 ($44K) on 2021-12-28, disclosed to the SEC on 2024-02-13.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.68 | 1,542 | $20K | 44.0% |
| 2 | $13.18 | 1,891 | $25K | 56.0% |
| Total | $12.96 avg | 3,433 | $44K | 100% |
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |